Daewon Pharmaceutical Co., Ltd. (003220) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daewon Pharmaceutical Co., Ltd. (003220:KRX), powered by AI.

Current Price
₩11,240
P/E Ratio
-182.7
Market Cap
252.1B
Sector
Healthcare
What is the Daewon Pharmaceutical Co., Ltd. stock price forecast?

Daewon Pharmaceutical Co., Ltd. is currently trading at ₩11,240. View real-time AI analysis on Alpha Lenz.

What is Daewon Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Daewon Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Daewon Pharmaceutical Co., Ltd.'s P/E ratio?

Daewon Pharmaceutical Co., Ltd.'s P/E ratio is -182.7.

Daewon Pharmaceutical Co., Ltd.

KRX · 003220
₩11,240+2,590(+29.94%)Market closedKRX regular session 09:00–15:30 KST
Ask about Daewon Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Daewon Pharmaceutical Co., Ltd. trades at a P/E of -182.7 (undervalued) with modest ROE of -0.5%.

Ask for details

Company Overview

Daewon Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company primarily engaged in the research, development, and manufacture of pharmaceutical products. Founded in 1958, the company has established itself in the healthcare industry by offering a diverse portfolio that includes prescription medicines, over-the-counter drugs, and nutritional supplements. Its product lineup addresses various therapeutic areas such as cardiovascular diseases, oncology, and pain management, catering to a wide demographic. Daewon Pharmaceutical leverages advanced biotechnology and rigorous quality controls in its manufacturing processes, ensuring high standards in product efficacy and safety. As a significant player in the pharmaceutical sector, the company contributes to public health by providing essential medical solutions, enhancing patient care, and supporting sustainable health systems. It operates with a commitment to innovation and regulatory compliance, positioning itself as a trusted partner in the medical and healthcare markets worldwide.

CEO백승열, BAEK JONATHAN IN
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,283

Company Statistics

FY 2025

Profile

₩252,086,032,920Market Cap
₩605,434,719,610Revenue
22.43MShares Out
1,283Employees

Margins

45.06%Gross
4.96%EBITDA
0.58%Operating
0.42%Pre-Tax
-0.66%Net

Valuation

-182.71P/E
0.95P/B
0.42EV/Sales
13.85EV/EBITDA
1386.17P/FCF

Growth (CAGR)

8.13%Rev 3Yr
14.44%Rev 5Yr
-56.64%Op Inc 3Yr
-31.99%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-0.67%ROA
-0.51%ROE
1.63%ROIC

Financial Health

₩47,196,486,750Cash & Cash Equivalents
₩291,876,250,670Net Debt
123.49%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daewon Pharmaceutical Co., Ltd. (ticker: 003220) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,283 employees. Market cap is $252.1B.

The current price is ₩11,240 with a P/E ratio of -182.71x and P/B of 0.95x.

ROE is -0.51% and operating margin is 0.58%. Annual revenue is $605.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daewon Pharmaceutical Co., Ltd. (003220) Stock Forecast 2026 ₩11,240 — Price, Financials & Analyst Targets | Alpha Lenz